Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Study describes the first known mutation to occur in lung cancer patients who have never smoked

Study describes the first known mutation to occur in lung cancer patients who have never smoked

1 Mar 2005
Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

22 Feb 2005
Blocking estrogen may be vitally important to improving survival from lung cancer

Blocking estrogen may be vitally important to improving survival from lung cancer

15 Feb 2005
50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

26 Jun 2004
Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

15 Jun 2004
Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness

Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness

29 Apr 2004

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback